COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.
Bou-Antoun S., Rokadiya S., Ashiru-Oredope D., Demirjian A., Sherwood E., Ellaby N., Gerver S., Grossi C., Harman K., Hartman H., Lochen A., Ragonnet-Cronin M., Squire H., Sutton JM., Thelwall S., Tree J., Bahar MW., Stuart DI., Brown CS., Chand M., Hopkins S.
The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.